



HAL
open science

Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis

Lorenzo Guglielmetti, Marie Jaspard, Damien Le Dû, Marie Lachâtre, Dhiba Marigot-Outtandy, Christine Bernard, Nicolas Veziris, Jérôme Robert, Yazdan Yazdanpanah, Eric Caumes, et al.

► To cite this version:

Lorenzo Guglielmetti, Marie Jaspard, Damien Le Dû, Marie Lachâtre, Dhiba Marigot-Outtandy, et al.. Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. European Respiratory Journal, 2017, 10.1183/13993003.01799-2016 . hal-01489714

HAL Id: hal-01489714

<https://hal.sorbonne-universite.fr/hal-01489714v1>

Submitted on 14 Mar 2017

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant**
2 **tuberculosis**

3
4 **AUTHORS:**

5 Guglielmetti Lorenzo (1, 2)*, Jaspard Marie (3)*, Le Dû Damien (1), Lachâtre Marie (4), Marigot-
6 Outtandy Dhiba (1, 5), Bernard Christine (2, 6), Veziris Nicolas (2, 6), Robert Jérôme (2, 6),
7 Yazdanpanah Yazdan (4), Caumes Eric (3)**, and Fréchet-Jachym Mathilde (1)** for the French
8 MDR-TB Management Group.

9 * L.G. and M.J. contributed equally to this manuscript (joint first authors)

10 ** M.F.-J. and E.C. contributed equally to this manuscript (joint senior authors).

11

12 **AFFILIATIONS:**

13 1. Sanatorium, Centre Hospitalier de Bligny, F-91640, Briis-sous-Forges, France

14 2. Sorbonne Université, UPMC Univ Paris 06, CR7, INSERM, U1135, Centre d'Immunologie et des
15 Maladies Infectieuses, CIMI, Team E13 (Bactériologie), F-75013, Paris, France

16 3. APHP, Service des Maladies Infectieuses et Tropicales, Hôpitaux Universitaires Pitié Salpêtrière-
17 Charles Foix, F-75013, Paris, France

18 4. APHP, Service des Maladies Infectieuses et Tropicales, Hôpital Bichat Claude Bernard, F-75018,
19 Paris, France

20 5. APHP, Service de Médecine Aigue Spécialisée, Hôpital Raymond Poincaré, F-92380, Garches,
21 France

22 6. APHP, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux
23 Antituberculeux (CNR-MyRMA), Bactériologie-Hygiène, Hôpitaux Universitaires Pitié Salpêtrière-
24 Charles Foix, F-75013, Paris, France

25

26 **French MDR-TB Management Group:** Andrejak C, Aubry A, Brossier F, Chadelat K, Dautzenberg
27 B, El Helali N, Henri B, Petitjean G, Raskine L, Rivoire B, Thouvenin G.

28

29 **KEYWORDS:**

30 MDR-TB; XDR-TB; off label; TMC207; adverse events.

31

32 **Corresponding author:**

33 Lorenzo Guglielmetti, M.D.

34 Sanatorium, Centre Hospitalier de Bligny, rue de Bligny, F-91640, Briis-sous-Forges, France

35 E-mail address: lorenzo.guglielmetti@gmail.com

36 Telephone : 0033 169263191

37 Fax : 0033 169263095

38

39 **Alternate corresponding author:**

40 Marie Jaspard

41 Service de maladies infectieuses et tropicales

42 Groupe hospitalier Pitié Salpêtrière

43 47-83 boulevard de l'hôpital

44 75651 Paris Cedex 13

45 Telephone: 0142160111

46 E-mail address: mariejaspard@hotmail.com

47

48 **SUMMARY OF THE ARTICLE:**

49 Treatment regimens including prolonged bedaquiline use are effective and overall well-tolerated in

50 MDR-TB patients.

52 **ABSTRACT:**

53 Bedaquiline, a recently-approved drug for the treatment of multidrug-resistant tuberculosis (MDR-
54 TB), is recommended for a duration of 24 weeks. There is scarce data on patients treated with this
55 drug outside clinical trials.

56 All MDR-TB patients who started treatment from 01/01/2011 to 31/12/2013 and received ≥ 30 days
57 of bedaquiline were included in a multicentre observational cohort.

58 Among 45 MDR-TB patients, 53% harbored isolates resistant to both fluoroquinolones and second-
59 line injectables and 38% to one of these drug classes. Median bedaquiline treatment duration was 361
60 days, and 33 patients (73%) received prolonged (>190 days) bedaquiline treatment. Overall, 36
61 patients (80%) had favorable outcome, five were lost-to-follow-up, three died, and one failed and
62 acquired bedaquiline resistance. No cases of recurrence were reported. Severe and serious adverse
63 events were recorded in 60% and 18% of patients. QTcF >500 ms values were recorded in 11% of
64 patients, but neither arrhythmias nor symptomatic cardiac side effects occurred. Bedaquiline was
65 discontinued in three patients following QTcF prolongation. No significant differences in outcomes,
66 or adverse events rates were observed between patients receiving standard and prolonged bedaquiline
67 treatment.

68 Bedaquiline-containing regimens achieved favourable outcomes in a large proportion of patients.

69 Prolonged bedaquiline treatment was overall well-tolerated in this cohort.

70

71 INTRODUCTION:

72 According to the World Health Organisation (WHO), in 2014 480000 people were newly diagnosed
73 with multidrug-resistant tuberculosis (MDR-TB), defined by resistance to isoniazid and rifampicin.
74 Among MDR-TB cases, 9% had extensively drug-resistant tuberculosis (XDR-TB) (resistance to any
75 fluoroquinolone and any second-line injectable drug).¹ MDR-TB treatment outcomes, although
76 heterogeneous in different settings, are overall unsatisfactory. A meta-analysis of MDR-TB patients
77 showed that treatment success rate was 64% with individualised regimens and 54% with standardized
78 treatment.² Two large meta-analyses comprising individual patient data consistently found an overall
79 treatment success rate of 54% and 56%.^{3,4} Treatment outcomes of XDR-TB are abysmal, ranging
80 from 27% to 40%.^{3,5} A study assessing the long-term outcomes of XDR-TB patients reported 11% of
81 favourable outcomes and 73% mortality at 5 years of follow-up.⁶

82 In order to face this emerging challenge, old drugs have been re-purposed, and new drugs have been
83 developed. Bedaquiline and delamanid have been recently approved for the treatment of MDR-TB.
84 A Phase II trial showed that bedaquiline improves treatment outcomes when compared to placebo.⁷
85 In an uncontrolled Phase II study, bedaquiline plus optimised background regimens achieved
86 favourable outcomes in 62.5% of patients.⁸ Preliminary reports of bedaquiline compassionate use
87 programs confirm these promising results.⁹⁻¹⁵ However, interim results also underline the risk of
88 experiencing culture reversion after the discontinuation of bedaquiline.¹⁰ To date, WHO recommends
89 the use of bedaquiline for a maximal duration of 24 weeks¹⁶ as no evidence is available supporting a
90 longer use, except for a recent case report.¹⁷ Nausea and hepatitis are the most common side effects
91 associated with bedaquiline.⁷⁻⁹ However, the main safety concern is cardiotoxicity. Although no
92 serious cardiac events or arrhythmias have been reported to date, bedaquiline has been shown to
93 prolong the QT interval, and the association with other drugs (such as clofazimine or moxifloxacin)
94 can enhance this effect.^{8,9} Due to the long terminal half-life of bedaquiline, a cumulative effect of
95 prolonged bedaquiline administration on QT interval could be postulated. We previously reported the

96 interim analysis of a cohort of MDR-TB patients receiving bedaquiline-containing regimens, with
97 six-month culture conversion rates of 96% and no relevant safety signals.⁹ The flexibility of the
98 regulatory framework of the compassionate use program in France has allowed the off-label use of
99 bedaquiline beyond 24 weeks in selected patients. The aim of this observational analysis is to
100 complement our previous findings with the evaluation, in a bigger cohort and up to 24 months after
101 treatment completion, of the treatment outcome and safety profile of individualized anti-TB regimens
102 containing prolonged bedaquiline treatment.

103 METHODS:**104 Patients and treatment**

105 A retrospective cohort was established including all MDR-TB patients treated with bedaquiline from
106 January, 2011, to December, 2013, and hospitalised at three French referral TB centres (Bligny, Pitié-
107 Salpêtrière and Bichat Hospitals). Patients were followed up after the end of treatment for up to 24
108 months or to the censor date (March 31, 2016). All TB cases were culture-proven. Standard definition
109 of MDR and XDR were used. Treatment outcomes were assigned according to WHO definitions.¹⁶
110 At the end of treatment, favourable outcomes were defined as the sum of cured and treatment
111 completed; all other outcomes were defined as unfavourable. All patients with favourable outcomes
112 were re-assessed at 12 and 24 months after end of treatment.

113 The treatment regimen was designed for each patient according to clinical features, phenotypic and
114 genotypic drug susceptibility testing (DST) results with the advice of the MDR-TB Consilium of the
115 National Reference Centre, which assessed the eligibility for bedaquiline treatment and its
116 prolongation beyond 24 weeks. The criteria that were used to identify eligible patients for bedaquiline
117 prolongation were the following: delayed microbiological response, weak treatment regimens due to
118 intolerance or drug resistance, and/or individual risk factors for poor outcomes (Table 1). In addition,
119 all WHO-recommended requirements for bedaquiline use were met, including active
120 pharmacovigilance and treatment monitoring.¹⁶

121 Bedaquiline was provided in the framework of the compassionate use program, and was administered
122 as recommended by the manufacturer. Standard bedaquiline treatment was defined as ≤ 190 days,
123 representing the standard duration of 24 weeks plus a buffer period of 3 weeks needed by the
124 Consilium to assess bedaquiline treatment duration. Prolonged bedaquiline treatment was defined as
125 >190 days. All drugs were administered as directly-observed treatment during hospitalisation.
126 Treatment and hospitalisation were offered free-of-charge to all patients, including migrants and
127 refugees. All patients were informed regarding the mechanism of the compassionate use program and

128 the safety profile of all drugs in the treatment regimen including bedaquiline. Data were
129 retrospectively extracted from medical records. Human research ethics approval for the study was
130 granted by the Institutional Review Board of the Bligny Hospital.

131

132 **Procedures**

133 Sputum smear and culture examinations were performed at treatment start, fortnightly up to culture
134 conversion, and monthly thereafter. Time to smear/culture conversion was measured from treatment
135 start to the first of two consecutive negative smear/culture results. Phenotypic DST for a panel of
136 first- and second-line anti-TB drugs was performed at the National Reference Centre using the
137 proportion method on Löwenstein-Jensen medium.¹⁸ Genotypic DST was obtained with
138 commercially-available line probe assays (GenoType® MTBDRplus, GenoType® MTBDRsl, Hain
139 Lifescience, GmbH, Germany) or DNA sequencing. From March 2013 onward, bedaquiline DST was
140 performed on Löwenstein-Jensen medium using the proportion method and a 64 mg/L critical
141 concentration for screening. Resistance was subsequently confirmed in TH11 medium. Bedaquiline
142 DST was performed at baseline and repeated in case of suspicion of treatment failure. A standard 12-
143 lead electrocardiogram was performed at baseline, at two weeks of treatment and monthly thereafter.
144 QT interval correction was calculated according to Fridericia (QTcF) and Bazett (QTcB) formula.¹⁹
145 A prolongation of the QT interval was defined as ≥ 60 ms increase during treatment. All adverse
146 events were defined and graded according to severity and seriousness on the basis of the US National
147 Institutes of Health Common Terminology Criteria for Adverse Events, version 4.0.²⁰ Severe adverse
148 events were defined as any event graded as level three, four, or five. Causality of adverse events was
149 evaluated according to the WHO-UMC system for standardised case causality assessment.²¹

150

151 **Statistical analysis**

152 Categorical variables were compared by using Fisher's exact test. Continuous variables were reported
153 as median and interquartile range (IQR), and compared by using the two-sample Wilcoxon-Mann-
154 Whitney test. Kaplan-Meier curves for culture conversion were estimated. The Mantel-Cox test was
155 used to compare time to culture conversion. The association between variables and time to culture
156 conversion was studied with a Cox proportional hazards model. Multivariable logistic regression was
157 used to estimate the association of QT interval prolongation and explanatory variables. Variables
158 associated in univariate analysis ($p < 0.20$) were considered for backward multivariable analysis. P-
159 values < 0.05 were considered as significant. Statistical analysis was performed using STATA
160 (StataCorp, Texas, USA). Results are reported according to the STROBE guidelines for observational
161 cohort studies.

162 RESULTS:**163 Socio-demographic and disease characteristics**

164 Among the 102 MDR-TB patients managed in the three centres during the study period, 45 patients
165 (44.1%) were treated with bedaquiline: 36 (80.0%) were born in Eastern Europe/Caucasus countries
166 (Table 2). Coinfection with HCV and HIV was present in 21 (46.7%) and two (4.4%) patients,
167 respectively. 34 (75.6%) patients previously received TB treatment. Overall, 44 patients had
168 pulmonary TB: 39 (88.6%) had lung cavities and 36 (81.8%) bilateral lung involvement. More
169 detailed baseline characteristics are reported in Supplementary Table 1.

170

171 Resistance patterns and treatment

172 A majority of the patients had XDR-TB (n=24, 53.3%). Out of the remaining patients, 11 (24.4%)
173 had strains with additional resistance to fluoroquinolones, and six (13.3%) to any second-line
174 injectable. Four (8.9%) had intolerance to either fluoroquinolones or second-line injectables. The
175 strains showed phenotypical resistance to a median of nine (IQR 7-11) drugs and a median of five (4-
176 6) mutations in resistance-conferring genes. All tested strains were susceptible to bedaquiline at
177 baseline (Table 3). The most frequently prescribed companion drugs are listed in Table 2. Median
178 treatment duration was 624 days (IQR 546-730); injectables were administered for a median of 341
179 days (IQR 228-455). The median duration of bedaquiline administration was 360 days (range, 31-
180 768). 15 patients (33.3%) received bedaquiline for the full treatment duration. Lung surgery, mostly
181 lobectomy, was performed in 12 (26.7%) patients after a median of 170 days (IQR 75-269) from
182 treatment start, and after sputum culture conversion in 75% of cases.

183

184 Treatment safety profile

185 During treatment, 44 (97.8%) patients experienced at least one adverse event (Table 4). The most
186 frequent were gastrointestinal side effects (n=32, 71.1%), oto-vestibular impairment (n=25, 55.6%)

187 and peripheral neuropathy (n=18, 40.9%). Severe and serious adverse events were recorded in 27
188 (60.0%) and seven (17.8%) patients, respectively. The most common severe adverse events were
189 peripheral neuropathy (n=13) and QTc prolongation (n=8). Severe and serious adverse events are
190 detailed in Supplementary Table 2. Bedaquiline was discontinued in three (6.7%) patients due to QTc
191 prolongation after 31, 203, and 279 days of treatment, respectively. One patient experienced
192 uncomplicated pancreatitis few weeks after bedaquiline discontinuation.

193 With regards to QT interval, only QTcF results will be reported, as no significant difference between
194 QTcF and QTcB results was observed. Figure 1 shows the evolution of QTcF during treatment in the
195 cohort. Overall, QTcF prolongation occurred in 13 (28.9%) patients. QTcF >500ms values were
196 recorded in five (11.1%) patients, all belonging to the prolonged bedaquiline group; in three cases the
197 QTcF prolongation occurred during the first 24 weeks of treatment. Median QTcF values remained
198 stable during the whole treatment duration in the prolonged bedaquiline group. The median of the
199 maximum QTcF increase was 36.2 (IQR 17.9-68.5) ms. In logistic regression analysis, both QTcF
200 >60 ms increase and QTcF >500 ms values were independently associated with co-administration of
201 moxifloxacin at 800 mg/day after adjustment for age, sex and treatment with other QT-prolonging
202 drugs. Methadone treatment was equally associated with >500 ms QTcF values. No association was
203 found with treatment with clofazimine, levofloxacin or moxifloxacin at 400 mg/day. The median of
204 the maximum QTcF increase during treatment was significantly higher in patients treated with high-
205 dose moxifloxacin treatment (data not shown). Neither clinical arrhythmia nor any cardiac event were
206 observed.

207

208 **Treatment outcomes**

209 Out of 41 patients with positive sputum cultures at treatment start, 23 (56.1%) and 40 (97.6%)
210 achieved culture conversion at 90 and 180 days, respectively. One patient achieved culture conversion
211 at eight months of treatment. Median time to sputum smear and culture conversion was 90 (IQR 36-

212 173) and 89 (IQR 45-107) days, respectively (Table 5). In a multivariate Cox proportional hazard
213 model, factors independently associated with faster time to culture conversion were HCV-negativity
214 (HR 2.64, confidence interval (CI) 1.34-5.19; $p=0.021$), the absence of lung cavities (HR 4.56, CI
215 1.41-14.75; $p=0.011$) and higher serum albumin levels at treatment start (HR 1.09, CI 1.02-1.16;
216 $p=0.010$). No association was found between prolonged bedaquiline treatment and time to culture
217 conversion after adjustment (Table 6).

218 At the end of treatment, 36 of the 45 patients (80.0%) had favourable outcome. Nine (20.0%) had
219 unfavourable outcome, including three deaths and one treatment failure with acquisition of resistance
220 to bedaquiline. During post-treatment follow-up, one patient died before the 12-months endpoint and
221 one died before the 24-months endpoint. No recurrences were recorded in the cohort (Table 5). The
222 characteristics of patients who died or experienced treatment failure are summarised in Table 7.

223 With regard to causality assessment, bedaquiline was considered as unlikely related to all deaths and
224 other serious adverse events.

225

226 **Comparison of standard and prolonged bedaquiline treatment regimens**

227 Overall, 12 (26.7%) and 33 patients (73.3%) received standard (median 183 days, IQR 168-185) and
228 prolonged (median 418 days, IQR 292-665) bedaquiline treatment. Patients receiving prolonged
229 bedaquiline treatment were more often previously treated for TB ($p<0.001$). They were more likely
230 to have XDR-TB, bilateral lung involvement, cavitary TB and strains with resistance to a greater
231 number of drugs, although these differences did not reach statistical significance (Supplementary
232 Table 3). No significant differences were recorded between the two groups regarding the incidence
233 of total, severe and serious adverse events, including liver enzyme elevation. No statistical difference
234 was found in the rate of QTcF prolongation and >500 ms values, nor in the maximum QTcF increase
235 recorded during treatment (Table 4). Patients in the prolonged treatment group were more frequently
236 sputum culture-positive at treatment start ($p=0.048$) and had slower time to culture conversion (91

237 versus 71 days, $p=0.021$) (Figure 2). Favourable and unfavourable treatment outcome rates at the end
238 of treatment and during post-treatment follow-up were comparable between the two groups (Table
239 5).

240 **DISCUSSION:**

241 We report successful outcomes in 80% of MDR-TB patients treated with bedaquiline-containing
242 regimens, with a high rate of adverse events.

243 This rate of success is remarkable, as our cohort included a substantial number of XDR-TB patients,
244 HCV-infected cases, and intravenous drug abuser undergoing methadone treatment. Similar treatment
245 outcomes are described in other high-resource settings, but these studies included fewer XDR-TB
246 patients.²²⁻²⁴ Previous studies including XDR-TB patients with low HIV-coinfection rates like in our
247 cohort reported lower success rates.^{25,26} Our results could be explained by multiple factors: treatment
248 follow-up in specialised centres with comprehensive patient support and appropriate management of
249 adverse events, free-of-charge treatment and social support for precarious populations, availability of
250 reliable DST by a reference laboratory, and tailored treatment regimens including lung surgery.²⁷

251 The duration of bedaquiline treatment was established according to individual clinical evaluation.
252 Interestingly, no difference in terms of efficacy and tolerance was found between standard and
253 prolonged bedaquiline groups, although the latter group arguably contained more difficult-to-treat
254 patients who achieved delayed sputum culture conversion. Moreover, prolonged bedaquiline
255 treatment courses could partly explain the better outcomes in our cohort with regards to bedaquiline-
256 treatment arms of the published Phase II clinical trials.^{7,8} Notably, almost all the patients in our cohort
257 received linezolid, a drug shown to improve treatment outcomes of MDR-TB patients.^{28,29} Other re-
258 purposed drugs, such as clofazimine³⁰ and carbapenems³¹⁻³² might have played a role. Finally, more
259 than half of the patients received a last-generation fluoroquinolone, and 22% received high-dose
260 moxifloxacin to overcome low-level fluoroquinolone resistance. A standardized nine-months
261 treatment regimen including a fourth-generation fluoroquinolone at high dose showed to achieve
262 good outcomes in patients harbouring strains with low-level fluoroquinolone resistance.³³

263 Overall, 11% of patients were lost to follow-up during treatment, and this rate markedly increased
264 during post-therapeutic follow-up. This finding is possibly related to the precarious state of the

265 patients, who are in the vast majority foreign-born and often migrating to seek for adequate health
266 care. The rate of loss to follow-up is similar to previous studies.²²⁻²⁴ In our cohort, five patients died,
267 three during treatment and two after the end of treatment. For the two patients who died during
268 treatment after developing neurological complications (Patients 3 and 4, Table 7), causality
269 assessment is challenging. The event was considered possibly related to linezolid because this drug
270 has well-documented neurological toxicity;^{28,29} and bedaquiline involvement was considered as
271 unlikely but can't be excluded. The single treatment failure (Patient 1, Table 7) was linked to
272 bedaquiline resistance during treatment with only three likely active drugs. There is a need for
273 efficient drug companions to protect new drugs from acquired resistance, as recently illustrated by
274 the case of a patient who developed sequential resistance to bedaquiline and delamanid.^{34,35}
275 Lung surgery was performed in 26.7% of our patients, who had cavitory disease, to attain sustained
276 culture conversion. The capacity of TB drugs to penetrate into lungs cavities and advanced tissue
277 necrosis is unknown and should lead to consider surgical treatment.³⁶
278 Toxicity is often a major issue in the long-term treatment needed for MDR-TB: in the placebo arm of
279 the C208 study, 98% of participants experienced adverse events.⁷ Observational cohorts corroborate
280 the high frequency of side effects.³⁷ In our study, all patients except one experienced at least one
281 adverse event, and 82% had to stop one drug because of side effects. More than half of our patients
282 experienced peripheral neuropathy, a known complication of prolonged linezolid administration.³⁸
283 QTc prolongation in our cohort was more frequent than what has been reported in bedaquiline-treated
284 patients in other studies,^{7,8,10,11} possibly because many patients in our cohort received other QT-
285 prolonging drugs, such as moxifloxacin, clofazimine, and other non-TB drugs like methadone.
286 Indeed, the administration of both high-dose moxifloxacin and methadone was associated with >500
287 ms QTcF values in our cohort. No association was found between clofazimine treatment and QTc
288 prolongation. However, studies with bigger sample size will be needed to confirm these results. There
289 was no statistical difference in the number of total adverse events, serious adverse events, and severe

290 adverse events between standard and prolonged bedaquiline groups. No difference was found in the
291 incidence of bedaquiline-associated adverse events, such as liver enzyme elevation, pancreatitis and
292 QTc prolongation. Although all episodes of >500 ms QTcF prolongation occurred in the prolonged
293 bedaquiline group, most patients experienced the prolongation during the first six months of
294 treatment. Median QTcF values remained stable during the whole treatment duration in the prolonged
295 bedaquiline group, irrespective of the cumulative exposure to the drug. Notably, no patient in the
296 cohort received both bedaquiline and delamanid, so no conclusion can be drawn on the tolerability of
297 the association of these two drugs.^{39,40}

298 Our study has multiple limitations. First, data were collected retrospectively, possibly leading to an
299 increase in the rate of loss to follow-up patients and to underreporting of adverse events. Second, the
300 small sample size of the cohort might not have enough power to show existing differences between
301 the standard and prolonged bedaquiline groups. Third, no control group of patients not receiving
302 bedaquiline was analysed. Finally, no measurement of bedaquiline levels in blood nor surgical
303 specimens was performed in the study.

304 In conclusion, our results show promising outcomes in a cohort including mostly XDR-TB patients,
305 and reassuring safety profile of prolonged bedaquiline administration. The prolongation of
306 bedaquiline treatment in selected patients with multiple risk factors could have contributed to the high
307 rate of favourable outcomes. We therefore advocate for extension of bedaquiline treatment beyond
308 24 weeks according to the individual patient's need and to predefined criteria (Table 1), as done for
309 other TB drugs.

310 The advent of new drugs offers us the opportunity to both improve outcomes and reduce the toxicity
311 of MDR/XDR-TB treatment. A rapid increase in the evidence supporting the use of bedaquiline will
312 hopefully provide additional treatment options for these patients.

313 **BIBLIOGRAPHY:**

314

- 315 1. World Health Organization. Global tuberculosis report 2015. World Health Organization
316 Document, **2015**; WHO/HTM/TB/2015.22.
- 317 2. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with
318 multidrug-resistant tuberculosis: systematic review and meta-analysis. *Lancet Infect Dis*,
319 **2009**; 9(3): 153–61.
- 320 3. Bonnet M, Bastard M, du Cros P, et al. Identification of patients who could benefit from
321 bedaquiline or delamanid: a multisite MDR-TB cohort study. *Int J Tuberc Lung Dis*,
322 **2016**; 20(2): 177–86.
- 323 4. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug-resistant pulmonary tuberculosis
324 treatment regimens and patient outcomes: an individual patient data meta-analysis of
325 9,153 patients. *PLoS Med*, **2012**; 9(8): e1001300.
- 326 5. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line
327 injectable drugs: impact on multidrug-resistant TB outcomes. *Eur Respir J*, **2013**; 42(1):
328 156–68.
- 329 6. Pietersen E, Ignatius E, Streicher EM, et al. Long-term outcomes of patients with
330 extensively drug-resistant tuberculosis in South Africa: a cohort study. *Lancet*, **2014**;
331 383(9924): 1230–9.
- 332 7. Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture
333 conversion with bedaquiline. *N Engl J Med*, **2014**; 371(8): 723–32.
- 334 8. Pym AS, Diacon AH, Tang S-J, et al. Bedaquiline in the treatment of multidrug- and
335 extensively drug-resistant tuberculosis. *Eur Respir J*, **2016**; 47(2): 564–74.

- 336 9. Guglielmetti L, Le Dû D, Jachym M, et al. Compassionate use of bedaquiline for the
337 treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim
338 analysis of a French cohort. *Clin Infect Dis*, **2015**; 60(2): 188–94.
- 339 10. Hewison C, Faqirzai J, Hayrapetian A, et al. Compassionate use of bedaquiline: interim
340 outcomes from the Armenian National Tuberculosis Control Office[abstract]. Union
341 World Conference, Cape Town, **2015**: PC-719-04.
- 342 11. Ndjeka N, Conradie F, Schnippel K, et al. Treatment of drug-resistant tuberculosis with
343 bedaquiline in a high HIV prevalence setting: an interim cohort analysis. *Int J Tuberc
344 Lung Dis*, **2015**; 19(8): 979–85.
- 345 12. Henry B, Revest M, Dournon N, et al. Preliminary favorable outcome for medically and
346 surgically managed extensively drug-resistant tuberculosis, France, 2009–2014. *Emerg
347 Infect Dis*, **2016**. <http://dx.doi.org/10.3201/eid2203.151130>
- 348 13. Guglielmetti L, Le Dû D, Veziris N, et al. Is bedaquiline as effective as fluoroquinolones
349 in the treatment of multidrug-resistant tuberculosis? *Eur Respir J*, **2016**. pii: ERJ-00411-
350 2016.
- 351 14. Tiberi S, De Lorenzo S, Centis R, et al. Bedaquiline in MDR/XDR-TB cases: first
352 experience on compassionate use. *Eur Respir J*, **2014**; 43: 289–92.
- 353 15. Pontali E, Sotgiu G, D'Ambrosio L, Centis R, Migliori GB. Bedaquiline and multidrug-
354 resistant tuberculosis: a systematic and critical analysis of the evidence. *Eur Respir J*,
355 **2016**; 47: 394–402.
- 356 16. World Health Organisation. Companion Handbook to the WHO Guidelines for the
357 Programmatic Management of Drug-Resistant Tuberculosis. Geneva, Switzerland:
358 World Health Organisation; **2014**. Accessed April 12, 2016.

- 359 17. Lewis JM, Hine P, Walker J, et al. First experience of effectiveness and safety of
360 bedaquiline for 18 months within an optimised regimen for XDR-TB. *Eur Respir J*,
361 **2016**; 47(5): 1581–4.
- 362 18. Barrera L, Cooreman E, de Dieu Iragena J, et al. Policy Guidance on Drug-Susceptibility
363 Testing (DST) of Second-Line Antituberculosis Drugs. Geneva: World Health
364 Organization; **2008**.
- 365 19. Aytemir K, Maarouf N, Gallagher MM, et al. Comparison of formulae for heart rate
366 correction of QT interval in exercise electrocardiograms. *Pacing Clin Electrophysiol*,
367 **1999**; 22(9): 1397–401.
- 368 20. Common Terminology Criteria for Adverse Events, version 4.0.
369 <http://evs.nci.nih.gov/ftp1/CTCAE>. Publish Date: May 28, 2009. Last accessed on
370 March 15, **2016**.
- 371 21. WHO-UMC system for standardised case causality assessment. [http://who-](http://who-umc.org/Graphics/24734.pdf)
372 [umc.org/Graphics/24734.pdf](http://who-umc.org/Graphics/24734.pdf). Last accessed on April 10, 2016.
- 373 22. Anderson LF, Tamne S, Watson JP, et al. Treatment outcome of multi-drug resistant
374 tuberculosis in the United Kingdom: retrospective-prospective cohort study from 2004 to
375 2007. *Euro Surveill*, **2013**; 18(40). pii:20601.
- 376 23. Marks SM, Flood J, Seaworth B, Hirsch-Moverman Y, Armstrong L, Mase S, et al.
377 Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-
378 resistant tuberculosis, United States, 2005-2007. *Emerg Infect Dis*. 2014
379 May;20(5):812–21.
- 380 24. van Altena R, de Vries G, Haar CH, et al. Highly successful treatment outcome of
381 multidrug-resistant tuberculosis in the Netherlands, 2000-2009. *Int J Tuberc Lung Dis*,
382 **2015**;19(4): 406–12.

- 383 25. Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment of extensively drug-
 384 resistant tuberculosis. *N Engl J Med*, **2008**; 359(6): 563–74.
- 385 26. Kim H-R, Hwang SS, Kim HJ, et al. Impact of extensive drug resistance on treatment
 386 outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. *Clin Infect*
 387 *Dis*, **2007**; 45(10): 1290–5.
- 388 27. Mordant P, Henry B, Morel S, et al. [Adjuvant surgical resection for multidrug-resistant
 389 tuberculosis: A review]. *Rev Mal Respir*, **2014**; 31(6): 511–24.
- 390 28. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-
 391 resistant tuberculosis. *N Engl J Med*, **2012**; 367(16): 1508–18.
- 392 29. Tang S, Yao L, Hao X, Zhang X, Liu G, Liu X, et al. Efficacy, safety and tolerability of
 393 linezolid for the treatment of XDR-TB: a study in China. *Eur Respir J*, **2015**; 45(1): 161–
 394 70.
- 395 30. Tang S, Yao L, Hao X, et al. Clofazimine for the treatment of multidrug-resistant
 396 tuberculosis: prospective, multicenter, randomized controlled study in China. *Clin Infect*
 397 *Dis*, **2015**; 60(9): 1361–7.
- 398 31. Diacon AH, van der Merwe L, Barnard M, et al. Beta-lactams against tuberculosis--new
 399 trick for an old dog? *N Engl J Med*. **2016**; 375: 393-394.
- 400 32. Tiberi S, Sotgiu G, D’Ambrosio L, et al. Comparison of effectiveness and safety of
 401 imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the
 402 treatment of MDR- and XDR-TB. *Eur Respir J*, **2016**; 47(6):1758-66.
- 403 33. Aung KJM, Van Deun A, Declercq E, et al. Successful “9-month Bangladesh regimen”
 404 for multidrug-resistant tuberculosis among over 500 consecutive patients. *Int J Tuberc*
 405 *Lung Dis*, **2014**; 18(10): 1180–7.
- 406 34. Bloemberg GV, Keller PM, Stucki D, et al. Acquired Resistance to Bedaquiline and
 407 Delamanid in Therapy for Tuberculosis. *N Engl J Med*, **2015**; 373(20): 1986–8.

- 408 35. Guglielmetti L, Le Dû D, Fréchet-Jachym M, Mitnick CD. Preventing Acquired
409 Resistance to Bedaquiline and Delamanid in Multidrug-Resistant Tuberculosis
410 Treatment Requires Optimal Management. *Amer J Respir Crit Care Med*, **2016**; in press.
- 411 36. Fox GJ, Mitnick CD, Benedetti A, et al. Surgery as an Adjunctive Treatment for
412 Multidrug-Resistant Tuberculosis: An Individual Patient Data Meta-analysis. *Clin Infect*
413 *Dis*, **2016**; 62(7): 887–95.
- 414 37. Bloss E, Kuksa L, Holtz TH, et al. Adverse events related to multidrug-resistant
415 tuberculosis treatment, Latvia, 2000-2004. *Int J Tuberc Lung Dis*, **2010**; 14, 275–81.
- 416 38. Bolhuis MS, Tiberi S, Sotgiu G, et al. Linezolid tolerability in multidrug-resistant
417 tuberculosis: a retrospective study. *Eur Respir J*, **2015**; 46(4): 1205–7.
- 418 39. Lachatre M, Rioux C, Du DL, et al. Bedaquiline plus delamanid for xdr tuberculosis.
419 *Lancet Infect Dis*. **2016**; 16: 294.
- 420 40. Tadolini M, Lingsang RD, Tiberi S, et al. Report of the first case, concerns and
421 challenges of treatment of severe XDR-TB with both delamanid and bedaquiline. *Eur*
422 *Respir J* **2016**; 48: 935–938.

423 **Table 1. Criteria and pre-requisites for prolonged bedaquiline treatment which have been used in this**
 424 **cohort**

Pre-requisites for bedaquiline prolongation beyond 24 weeks	Definition
Good tolerability	No serious side effects linked to bedaquiline during the first 24 weeks of treatment.
Informed consent	Patient should be correctly informed about the potential risks and benefits, as well as on the available evidence on prolonged bedaquiline treatment.
Closely monitored treatment	Treatment should be monitored closely according to available guidance for timely detection and management of adverse events.
Expert opinion by an independent organization	Expert opinion should be provided by an external organism (ie. national or international consilium).
Pharmacovigilance system	A proper pharmacovigilance system should be in place.
Criteria for bedaquiline prolongation beyond 24 weeks	Definition
Late microbiological response	Patient still sputum culture-positive after 3 months or more of treatment and not meeting the criteria for treatment failure
Insufficient number of effective drugs in the treatment regimen	Less than 4 effective drugs* left in the treatment regimen if bedaquiline is discontinued. The paucity of effective drugs in the treatment regimen may be due to drug resistance pattern, adverse events or any other contraindication.
Presence of risk factors for poor treatment outcome	Presence of risk factor for unfavourable treatment outcome, including: <ul style="list-style-type: none"> • Low BMI (<18.5 kg/m²) • High sputum smear bacillary load (2+/3+) • HIV-positivity • Extensive / advanced pulmonary disease • Contraindication to surgery

425 * Effective drug = never used before in a failing regimen, susceptible according to a reliable DST result

426 **Table 2. Socio-demographic characteristics, disease features and treatment regimens of the 45 patients**

Categorical variables	n (%)
Sex, male	36 (80.0)
Foreign-born	44 (97.8)
• Eastern Europe and Caucasus region	36 (80.0)
• Africa	5 (11.1)
• Asia	3 (6.7)
HIV infection	2 (4.4)
HCV infection	21 (46.7)
Intravenous drug use with methadone substitution	6 (13.3)
Pulmonary tuberculosis localization	44 (97.8)
Bilateral lung involvement (N=44)	36 (81.8)
Cavities on chest radiography (N=44)	39 (88.6)
Sputum smear-positive at treatment start	42 (93.3)
Sputum culture-positive at treatment start	41 (91.1)
Any previous tuberculosis treatment	34 (75.6)
Drugs contained in the treatment regimen	
Ethambutol	20 (44.4)
Pyrazinamide	19 (42.2)
Amikacin	32 (71.1)
Capreomycin	3 (6.7)
Moxifloxacin (400 mg / 800 mg daily)	14 (31.1) / 10 (22.2)
Levofloxacin (1000 mg daily)	8 (17.8)
Ethionamide	11 (24.4)
Para-amino salicylic acid	40 (88.9)
Cycloserine	32 (71.1)
Linezolid	43 (95.6)
Clofazimine	20 (44.4)
Imipenem / clavulanic acid	28 (62.2)
Meropenem / clavulanic acid	2 (4.4)
Continuous variables	median (interquartile range)
Age at admission (years)	38 (30 – 42)
Serum albumin (g/dl)	32.5 (27.5 – 36.9)
Body Mass Index (kg/m ²)	19.6 (17.8 – 22.0)
N of drugs included in the treatment regimen	7 (6 – 8)

427 Fq: fluoroquinolones; SLI: second-line injectable drugs; DST: drug susceptibility testing.
428

429 **Table 3. Baseline phenotypic and genotypic resistance pattern of the strains isolated from the 45**
 430 **patients.**

Antibiotic (gene)	Phenotypic resistance	Genotypic resistance
Rifampicin (<i>rpoB</i>)	45/45 (100)	45/45 (100)
Isoniazid (<i>inhA</i> promoter, <i>katG</i>)	45/45 (100)	45/45 (100)
Pyrazinamide (<i>pncA</i>)	17/19 (89.5)	32/45 (71.1)
Ethambutol (<i>embB</i>)	33/44 (75.0)	18/45 (40.0)
Streptomycin	41/45 (91.1)	n. d.
Amikacin (<i>rrs</i>)	14/45 (31.1)	12/45 (26.7)
Kanamycin (<i>rrs</i>)	28/45 (62.2)	12/45 (26.7)
Capreomycin (<i>rrs</i>)	17/45 (37.8)	12/45 (26.7)
Ofloxacin (<i>gyrA</i> , <i>gyrB</i>)	35/45 (77.8)	33/45 (73.3)
Moxifloxacin* (<i>gyrA</i> , <i>gyrB</i>)	24/45 (53.3)	33/45 (73.3)
Ethionamide (<i>inhA</i> promoter, <i>ethA</i> , <i>ethR</i>)	38/44 (86.4)	38/44 (86.4)
Para-amino salicylic acid	14/45 (31.1)	n. d.
Cycloserine	24/45 (54.5)	n. d.
Linezolid	0/45	n. d.
Bedaquiline	0/22	n. d.

431 Figures represent resistant strains / tested strains (%) for each drug. Sequenced genes and promoters are
 432 specified for each drug.

433 n.d. = not done

434 * Moxifloxacin was tested at 2 mg/L in order to distinguish between low and high-level resistance. Strains
 435 which were ofloxacin resistant but moxifloxacin susceptible were considered low-level resistant to
 436 moxifloxacin

437

438 **Table 4. Treatment safety in the whole cohort and comparison between patients receiving standard**
 439 **(≤190 days) or prolonged (>190 days) bedaquiline treatment**

Categorical variables, n (%)	Whole cohort (n=45)	Standard Bdq treatment (n=12)	Prolonged Bdq treatment (n=33)	p-value*
Any AE	44 (97.8)	12 (100)	32 (97.0)	1.000
Any severe AE	28 (62.2)	5 (41.7)	23 (69.7)	0.163
Any serious AE	7 (15.6)	1 (8.3)	6 (18.2)	0.655
At least one drug stopped due to AEs	37 (82.2)	8 (66.7)	29 (87.9)	0.181
Bedaquiline stopped due to AEs	3 (6.7)	1 (8.3)	2 (6.1)	1.000
Liver enzyme elevation	17 (37.8)	6 (50.0)	11 (33.3)	0.325
Pancreatitis	1 (2.2)	1 (8.3)	0	0.267
QTcF >500 ms	5 (11.1)	0	5 (15.2)	0.303
QTcF >60 ms increase	13 (28.9)	4 (33.3)	9 (27.3)	0.721
Continuous variables, median (interquartile range)	Whole cohort (n=45)	Standard Bdq treatment (n=12)	Prolonged Bdq treatment (n=33)	p-value*
Maximum QTcF increase during treatment	36.2 (17.9 – 68.5)	31.9 (16.0 – 73.3)	41.6 (19.7 – 63.7)	0.437

440 AE = adverse event

441 * Comparison between patients with standard and prolonged bedaquiline treatment, calculated with the Wilcoxon's test
 442 for continuous variables and Fisher's exact test for categorical variables.

443

444 **Table 5. Treatment outcomes of the whole cohort and comparison between patients receiving standard**
 445 **(≤190 days) or prolonged (>190 days) bedaquiline treatment**

Categorical variables, n (%)	Whole cohort (n=45)	Standard Bdq treatment (n=12)	Prolonged Bdq treatment (n=33)	p-value*
Favourable outcomes	36 (80.0)	9 (75.0)	27 (81.8)	0.682
- Cured	34 (75.6)	7 (58.3)	27 (81.8)	0.131
- Treatment completed	2 (4.4)	2 (16.7)	0	0.067
Unfavourable outcomes	9 (20.0)	3 (25.0)	6 (18.2)	1.000
- Lost to follow-up	5 (11.1)	2 (16.7)	3 (9.1)	0.598
- Died	3 (6.7)	1 (8.3)	2 (6.1)	1.000
- Treatment failed	1 (2.2)	0	1 (3.0)	1.000
Follow-up at 12 months	(n=36)**	(n=9)**	(n=27)**	
- No recurrence	23 (63.9)	4 (44.4)	19 (70.4)	0.235
- Lost to follow-up	9 (25.0)	5 (55.6)	4 (14.8)	0.026
- Died	1 (2.8)	0	1 (3.7)	1.000
- Censored	3 (8.3)	0	3 (11.1)	0.558
Follow-up at 24 months	(n=23)**	(n=4)**	(n=19)	
- No recurrence	4 (17.4)	1 (25.0)	3 (15.8)	1.000
- Lost to follow-up	2 (8.7)	0	2 (10.5)	1.000
- Died	1 (3.7)	1 (25.0)	0	0.174
- Censored	16 (69.6)	2 (50.0)	14 (73.7)	0.557
Continuous variables, median (interquartile range)	Whole cohort (n=45)	Standard Bdq treatment (n=12)	Prolonged Bdq treatment (n=33)	p-value*
Time to sputum smear conversion	90 (36 – 173)	71 (22 – 90)	110 (47 – 195)	0.002
Time to sputum culture conversion	89 (45 - 107)	71 (53 – 88)	91 (43 – 114)	0.021

446 *Comparison between patients with standard and prolonged bedaquiline treatment, calculated with the Wilcoxon's test
 447 for continuous variables and Fisher's exact test for categorical variables.

448 **Patients eligible for follow-up are those with favourable outcomes at previous time point.

449 **Table 6. Univariate and multivariate Cox proportional hazards models assessing the association of**
 450 **factors with time to culture conversion.**

Variables	Univariate HR (95% C. I.)	P	Multivariate HR (95% C. I.)	p
Age		0.765		
Sex, male	0.54 (0.24-1.22)	0.159		0.611
HCV–negative	2.64 (1.34-5.19)	0.005	2.35 (1.14-4.88)	0.021
Serum albumin	1.11 (1.05-1.18)	<0.001	1.09 (1.02-1.16)	0.010
Body mass index		0.407		
Absence of lung cavities	5.35 (1.70-16.87)	0.014	4.56 (1.41-14.75)	0.011
Bilateral lung involvement	0.31 (0.13-0.73)	0.013		0.270
Sputum smear positive at treatment start	0.16 (0.02-1.34)	0.173		0.524
Treatment with ethambutol		0.400		
Treatment with pyrazinamide	0.52 (0.27-1.02)	0.051		0.424
Treatment with any second- line injectable		0.892		
Treatment with any fluoroquinolone	1.71 (0.89-3.29)	0.105		0.334
Treatment with ethionamide	2.09 (0.97-4.53)	0.077		0.051
Surgery		0.877		
Standard bedaquiline treatment duration	0.39 (0.17-0.89)	0.035		0.702
HR = hazard ratio; C. I. = confidence interval.				

451

452

- **Table 7. Summary of the characteristics and evolution of patients who died or experienced treatment failure**

453

Patient	Outcome	TB diagnosis	Initial treatment regimen	Description
1	Treatment failure	Extended pulmonary XDR-TB	Bdq, Am, Eto, PAS, Lzd, Cfz	Lzd, PAS and Am had to be stopped because of peripheral neuropathy, gastrointestinal intolerance and hearing loss. After achieving initial culture conversion, the patient reverted to sputum culture positivity at 14 months of treatment, acquiring resistance to Bdq.
2	Death	Extended pulmonary MDR-TB	Am, Mfx, Cs, PAS, Lzd, Cfz	The patient died from dissemination of a pharyngolaryngeal cancer after 9 months of treatment. Bdq was started at month 4 and stopped at month 5 because of QTcF interval prolongation.
3	Death	Extended pulmonary XDR-TB	Bdq, Cs, PAS, Lzd, Ipm/Cln, Amx/Clv	The patient achieved sputum culture conversion at month 4 of treatment. Since month 15 of treatment, he developed peripheral neuropathy, difficulty to swallow, myositis, myoclonia, and psychiatric disorders. He died one month later with no obvious diagnosis. No signs of serotonin syndrome were present, and the patient did not receive any serotonin-inducing concomitant medication. Autopsy found no explanation for the death.
4	Death	Extended pulmonary XDR-TB	Bdq, Am, PAS, Lzd, Ipm/Cln, Amx/Clv	The patient achieved sputum culture conversion at month 4 of treatment, after performing lung surgery. From month 9 of treatment, he gradually developed peripheral neuropathy and neuro-psychiatric disorders. After a septic shock due to catheter infection at month 21, he was diagnosed with polyradiculoneuropathy and brainstem disorder. He died few days later. No signs of serotonin syndrome were present, and the patient did not receive any serotonin-inducing concomitant medication. Autopsy was not performed.
5	Death (during follow-up)	Extended pulmonary XDR-TB	Bdq, Cm, Mfx, Cfz, Lzd, Ipm/Cln, Amx/Clv	The patient underwent lung surgery at month 1, and was declared cured after 19 months of treatment. He died of overdose of recreational drugs one month after the end of treatment.

6	Death (during follow-up)	Extended pulmonary XDR-TB	Bdq, E, Z, Am, Mfx, PAS, Lzd	The patient suffered from type-1 diabetes and chronic renal insufficiency. He was declared cured after 18 months of treatment, and had no sign of recurrence He died of terminal renal failure 20 months after the end of treatment.
Bdq=bedaquiline; E=ethambutol, Z=pyrazinamide, Am=amikacin; Cm=capreomycin; Mfx=moxifloxacin; Eto=ethionamide; Cs=cycloserine, PAS=para-aminosalicylic acid; Lzd=linezolid, Cfz=clofazimine; Ipm/Cln=imipenem/cilastatin; Amx/Clv=amoxicilline/clavulanic acid.				

455 **Funding source:**

456 Funding: no funding to declare.

457

458 **Acknowledgments:**

459 The authors thank all patients who took part to the study. They also acknowledge all physicians and
460 microbiologists who provided data for the study. The authors acknowledge Dr. Francis Varaine
461 (Médecins Sans Frontières, France) for providing useful comments on the manuscript.

462

463 **Authors contributions:**

464 L.G. made a substantial contribution to the conception and design of the work, to the acquisition,
465 analysis and interpretation of data, performed statistical analysis, wrote the manuscript, critically
466 revised the manuscript, and gave final approval of the current version to be published. M.J. and M.F.-
467 J. made a substantial contribution to the conception and design of the work, to the acquisition, analysis
468 and interpretation of data, wrote the manuscript, critically revised the manuscript, and gave final
469 approval of the current version to be published. D.L.D. made a substantial contribution to the conception
470 and design of the work, to the acquisition, analysis and interpretation of data, critically revised the
471 manuscript, and gave final approval of the current version to be published. M.L., D.M.O., C.B., N.V.,
472 J.R., Y.Y., and E.C. made a contribution to the acquisition of the data, critically revised the
473 manuscript, and gave final approval of the current version to be published. All authors agree to be
474 accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity
475 of any part of the work are appropriately investigated and resolved.

476

477 **Declaration of interests:**

478 C.B., N.V. and J.R. belong to a research team which has received research grants from Janssen
479 Pharmaceutica. M.F.-J. received payment for lectures related to multidrug-resistant tuberculosis from
480 Astra-Zeneca. M.J. received personal fee to participate to a tuberculosis workshop from Janssen

481 Pharmaceutica. Y.Y. received personal fees from AbbVie, BMS, Gilead, MSD, Roche, Johnson &
482 Johnson, ViiV Healthcare, Pfizer, and Janssen. All other authors report no potential conflict of
483 interests for any aspect of this work.

484

485 **Ethics committee approval:**

486 Human research ethics approval for the study was granted by the Institutional Review Board of the
487 Bligny Hospital (Briis-sous-Forges, France).